Значение биомаркеров при хронической обструктивной болезни легких


https://doi.org/10.18093/0869-0189-2013-0-3-105-110

Полный текст:


Аннотация

Значение биомаркеров при хронической обструктивной болезни легких.

Об авторах

Г. Е. Баймаканова
ФГБУ "НИИ пульмонологии" ФМБА России
Россия

д. м. н., старший научный сотрудник лаборатории интенсивной терапии и дыхательной недостаточности 

105077, Москва, ул. 11-я Парковая, 32, корп. 4. Тел. / факс: (495) 465-74-15.



С. Н. Авдеев
ФГБУ "НИИ пульмонологии" ФМБА России
Россия

д. м. н., проф., руководитель клинического отдела 

105077, Москва, ул. 11-я Парковая, 32, корп. 4. тел. / факс: (495) 465-52-64.



Список литературы

1. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI / WHO workshop report. The 2011 report is available on www.goldcopd.com

2. Biomarkers and surrogate endpoints: clinical research and applications. Amsterdam: Elsevier Scientific; 2000. 1–7. Clin. Pharmacol. Ther. 2001; 69: 89–95.

3. Cazzola M., Novelli G. Biomarkers in COPD. Pulm. Pharmacol. Ther. 2010; 23: 493–500.

4. Barnes P., Chowdhury B., Kharitonov S. et al. Pulmonary biomarkers in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2006; 174: 6–14.

5. Franciosi L.G., Page C.P., Celli B.R. et al. Markers of disease severity in chronic obstructive pulmonary disease. Pulm. Pharmacol. Ther. 2006; 19: 189–199.

6. Cazzola M., MacNee W., Martinez F.J. et al. Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur. Respir. J. 2008; 31: 416–469.

7. Jones P.W., Agusti A.G.N. Outcomes and markers in the assessment of chronic obstructive pulmonary disease. Eur. Respir. J. 2006; 27: 822–832.

8. Koutsokera A., Stolz D., Loukides S., Kostikas K. Systemic biomarkers in exacerbations of COPD: The evolving clinical challenge. Chest 2012; 141 (2): 396–405.

9. Pinto,Plata V.M., Mullerova H., Toso J.F. et al. C-reactive protein in patients with COPD, control smokers and nonsmokers. Thorax 2006; 61: 23–28.

10. Agusti A., Edwards L.D., Rennard S.I. et al. Persistent Systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype. PLoS ONE 2012; 7 (5): 37483.

11. Man S.F., Connett J.E., Anthonisen N.R. et al. C-reactive protein and mortality in mild to moderate chronic obstructive pulmonary disease. Thorax 2006; 61: 849–853.

12. Shaaban R., Kony S., Driss F. et al. Change in C-reactive protein levels and FEV1 decline: a longitudinal populationbased study. Respir. Med. 2006; 100: 2112–2120.

13. Dahl M., Vestbo J., Lange P. et al. C-reactive protein as a predictor of prognosis in chronic obstructive pulmonarydisease. Am. J. Respir. Crit. Care Med. 2007; 175: 250–255.

14. de Torres J.P., Cordoba,Lanus E., López,Aguilar C. et al. C-reactive protein levels and clinically important predictive outcomes in stable. COPD patients Eur. Respir. J. 2006; 27: 902–907.

15. Man S.F., Xing L., Connett J.E. et al. Circulating fibronectin to C-reactive protein ratio and mortality: a biomarker in COPD? Eur. Respir. J. 2008; 32: 1451–1457.

16. Hurst J.R., Donaldson G.C., Perera W.R. et al. Use of plasma biomarkers at exacerbation of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2006; 174: 867–874.

17. Баймаканова Г.Е., Зубаирова П.А., Авдеев С.Н., Чучалин А.Г. Особенности клинической картины и течения внебольничной пневмонии у пациентов с хронической обструктивной болезнью легких. Пульмонология 2009; 2: 33–41.

18. Broekhuizen R., Wouters E.F.M., Creutzberg E.C., Schols A.M.W.J. Raised CRP levels mark metabolic and functional impairment in advanced COPD. Thorax 2006; 61: 17–22.

19. Smith R.P., Lipworth B.J., Cree I.A. et al. C-reactive protein: a clinical marker in community-acquired pneumonia. Chest 1995; 108: 1288–1291.

20. Flanders S.A., Stein J., Shochat G. et al. Performance of a bedside C-reactive protein test in the diagnosis of community-acquired pneumonia in adults with acute cough. Am. J. Med. 2004; 116: 529–535.

21. Almirall J., Bolibar I., Toran P. et al. Contribution of C-reactive protein to the diagnosis and assessment of severity of community-acquired pneumonia. Chest 2004; 125: 1335–1342.

22. Almirall J., Mesalles E., Klamburg J. et al. Prognostic factors of pneumonia requiring admission to the intensive care unit. Chest 1995; 107: 511–516.

23. Castro,Guardiola A., Armengou,Arxe A., Viejo,Rodriguez A. et al. Differential diagnosis between community-acquired pneumonia and non-pneumonia diseases of the chest in the emergency ward. Eur. J. Intern. Med. 2000; 11: 334–339.

24. Dev D., Sankaran E.W.R., Cunnife J. et al. Value of C-reactive protein in exacerbation of chronic obstructive pulmonary disease. Respir. Med. 1998; 92: 664–667.

25. Weis N., Almdal T. C reactive protein can it be used as a marker of infection in patients with exacerbation of chronic obstructive pulmonary diseases. Eur. J. Intern. Med. 2006; 17: 88–91.

26. Soler N., Esperatti M., Ewig S. et al. Sputum purulenceguided antibiotic use in hospitalised patients with exacerbations of COPD. Eur. Respir. J. 2012; 40: 1344–1353.

27. Miravitlles M., Kruesmann F., Haverstock D. et al. Sputum colour and bacteria in chronic bronchitis exacerbations: a pooled analysis. Eur. Respir. J. 2012; 39: 1354–1360.

28. Bathoorn E., Liesker J.J., Postma D.S. et al. Change in inflammation in out-patient COPD patients from stable phase to a subsequent exacerbation. Int. J. Chron. Obstruct. Pulm. Dis. 2009; 4: 101–109.

29. Bozinovski S., Hutchinson A., Thompson M. et al. Serum amyloid a is a biomarker of acute exacerbations of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2008; 177 (3): 269–278.

30. Creutzberg E.C., Wouters E.F., Vanderhoven,Augustin I.M. et al. Disturbances in leptin metabolism are related to energy imbalance during acute exacerbations of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2000; 162 (4, Pt 1): 1239–1245.

31. Stolz D., Breidthardt T., Christ,Crain M. et al. Use of B-type natriuretic peptide in the risk stratification of acute exacerbations of COPD. Chest 2008; 133 (5): 1088–1094.

32. Daniels J.M., Schoorl M., Snijders D. et al. Procalcitonin vs C-reactive protein as predictive markers of response to antibiotic therapy in acute exacerbations of COPD. Chest 2010; 138 (5): 1108–1115.

33. Daubin C., Parienti J.J., Vabret A. et al. Procalcitonin levels in acute exacerbation of COPD admitted in ICU: a prospective cohort study. BMC Infect. Dis. 2008; 8: 145.

34. Stolz D., Christ,Crain M., Morgenthaler N.G. et al. Plasma pro-adrenomedullin but not plasma pro-endothelin predicts survival in exacerbations of COPD. Chest 2008; 134 (2): 263–272.

35. Christ,Crain M., Jaccard,Stolz D., Bingisser R. et al. Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial. Lancet 2004; 363 (9409): 600–607.

36. Stolz D., Christ,Crain M., Bingisser R. et al. Antibiotic treatment of exacerbations of COPD: a randomized, controlled trial comparing procalcitonin-guidance with standard therapy. Chest 2007; 131 (1): 9–19.

37. Phua J., Koay E.S., Zhang D. et al. Soluble triggering receptor expressed on myeloid cells-1 in acute respiratory infections. Eur. Respir. J. 2006; 28 (4): 695–702.

38. Kherad O., Kaiser L., Bridevaux P.O. et al. Upper viral respiratory infection, biomarkers and COPD exacerbations. Chest 2010; 138 (4): 896–904.

39. Jelic S., Le Jemtel T.H. Diagnostic usefulness of B-type natriuretic peptide and functional consequences of muscle alterations in COPD and chronic heart failure. Chest 2006; 130: 1220–1230.

40. Grasso S., Leone A., De Michele M. et al. Use of N-terminal pro-brain natriuretic peptide to detect acute cardiac dysfunction during weaning failure in difficult-to-wean patients with chronic obstructive pulmonary disease. Crit. Care Med. 2007; 35: 96–105.

41. Abroug F., Ouanes,Besbes L., Nciri N. et al. Association of left-heart dysfunction with severe exacerbation of chronic obstructive pulmonary disease: diagnostic performance of cardiac biomarkers. Am. J. Respir. Crit. Care Med. 2006; 174: 990–996.

42. Tung R.H., Camargo C.A., Krauser D. Amino-terminal probrain natriuretic peptide for the diagnosis of acute heart failure in patients with previous obstructive airway disease. Ann. Emerg. Med. 2006; 48: 66–74.

43. Баймаканова Г.Е., Авдеев С.Н. Диагностическая и прогностическая значимость N-отрезка мозгового натрийуретического пептида (Nt-proBNP) при обострении ХОБЛ. Пульмонология 2011; 6: 80–86.

44. Brekke P.H., Omland T., Holmedal S.H. et al. Troponin T elevation and long-term mortality after chronic obstructive pulmonary disease exacerbation. Eur. Respir. J. 2008; 31: 563–570.

45. Baillard C., Boussarssar M., Fosse J.P. et al. Cardiac troponin I in patients with severe exacerbation of chronic obstructive pulmonary disease. Intensive Care Med. 2003; 29: 584–589.

46. Martins C.S., Rodrigues M.J.O., Miranda V.P., Nunes J.P.L. Prognostic value of cardiac troponin I in patients with COPD acute exacerbation. Netherlands J. Med. 2009; 67 (10): 341–349.

47. Chang C.L., Robinson S.C., Mills G.D. et al. Biochemical markers of cardiac dysfunction predict mortality in acute exacerbations of COPD. Thorax 2011; 66: 764–768.

48. Oktay B., Ardic S. Is heart type fatty acid binding protein a marker of cardiac damage in patients with acute attacks of chronic obstructive pulmonary disease? Eur. Respir. J. 2009; Р 3111: 103s.

49. Seyhan E.C., Önür I., Sökücüu S. et al. Relation of troponin and heart type fatty acid protein (H-FABP) levels to echocardiographic and cardiac infarction injury score (CIS) with patients with respiratory insufficiency due to COPD attack. Eur. Respir. J. 2009; P695: 123s.

50. Баймаканова Г.Е., Авдеев С.Н. Диагностическая и прогностическая роль повышения биомаркеров повреждения (тропонина I, белка, связывающего жирные кислоты) при обострении хронической обструктивной болезни легких. Пульмонология 2012; 1: 66–74.

51. Sin D.D., Vestbo J. Biomarkers in chronic obstructive pulmonary disease. Proc. Am. Thorac. Soc. 2009; 6: 543–545.


Дополнительные файлы

Для цитирования: Баймаканова Г.Е., Авдеев С.Н. Значение биомаркеров при хронической обструктивной болезни легких.  Пульмонология. 2013;(3):105-110. https://doi.org/10.18093/0869-0189-2013-0-3-105-110

For citation: Baymakanova G.E., Avdeev S.N. A role of biomarkers in chronic obstructive pulmonary disease. Russian Pulmonology. 2013;(3):105-110. (In Russ.) https://doi.org/10.18093/0869-0189-2013-0-3-105-110

Просмотров: 345

Обратные ссылки

  • Обратные ссылки не определены.


ISSN 0869-0189 (Print)
ISSN 2541-9617 (Online)